A Randomized Controlled Study of YONDELIS (Trabectedin) or Dacarbazine for the Treatment of Advanced Liposarcoma or Leiomyosarcoma Previously Treated With an Anthracycline and Ifosfamide

Trial Profile

A Randomized Controlled Study of YONDELIS (Trabectedin) or Dacarbazine for the Treatment of Advanced Liposarcoma or Leiomyosarcoma Previously Treated With an Anthracycline and Ifosfamide

Completed
Phase of Trial: Phase III

Latest Information Update: 05 Jun 2018

At a glance

  • Drugs Trabectedin (Primary) ; Dacarbazine
  • Indications Leiomyosarcoma; Liposarcoma; Soft tissue sarcoma
  • Focus Registrational; Therapeutic Use
  • Acronyms SAR3007
  • Sponsors Janssen Research & Development
  • Most Recent Events

    • 05 Jun 2018 Results of a genomic analysis presented at the 54th Annual Meeting of the American Society of Clinical Oncology.
    • 27 Nov 2017 Results of pooled data from two trials (NCT01273493 and NCT01343277) assessing pharmacokinetics and safety of trabectedin in patients with pre-existing hepatic impairment, were published in the Investigational New Drugs.
    • 12 Sep 2017 Results of matched indirect comparison from SAR 3007 and PALETTE trials presented at the 42nd European Society for Medical Oncology Congress.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top